Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 629-634, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dutton, J.
Right arrow Articles by Roberts, N. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dutton, J.
Right arrow Articles by Roberts, N. B.

Clinical Chemistry, Vol 39, 629-634, Copyright © 1993 by American Association for Clinical Chemistry

Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor

J Dutton, LG Copeland, JR Playfer and NB Roberts
Department of Clinical Chemistry, Royal Liverpool University Hospital, UK.

We have established a method for measuring L-dopa in plasma and urine, including the metabolites dopamine and L-dopac, using separation by ion- pair reversed-phase HPLC and quantification with an electrochemical detector. The assay was applied to the therapeutic monitoring of elderly patients with established Parkinson disease being treated with L-dopa plus a dopa decarboxylase inhibitor. Plasma L-dopa was evaluated in relation to dosage and postdose sampling time in 71 outpatients with Parkinson disease. L-Dopa concentrations were greatest in the patients taking the highest dosages prescribed and decreased significantly with increasing time after postdose sampling. Comparison of plasma L-dopa concentrations with a published therapeutic range established by intravenous administration of L-dopa was helpful in assessing the suitability of each patient's drug dosage, assessing patients' compliance, and avoiding overdosage but was not useful in the overall clinical assessment of progression of disease or of the long-term therapeutic response. Urine measurements confirmed the plasma concentrations but showed no further advantage. The recommended time for sample collection is between 1.5 and 3 h after the first morning dose. Plasma is the preferred matrix but if blood sampling is difficult, particularly from elderly/infirm individuals, an untimed urine collection could be used.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Clin. Nutr.Home page
T. A Sentongo, E. J Semaeo, N. Stettler, D. A Piccoli, V. A Stallings, and B. S Zemel
Vitamin D status in children, adolescents, and young adults with Crohn disease
Am. J. Clinical Nutrition, November 1, 2002; 76(5): 1077 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Dutton, A. J. Hodgkinson, G. Hutchinson, and N. B. Roberts
Evaluation of a New Method for the Analysis of Free Catecholamines in Plasma Using Automated Sample Trace Enrichment with Dialysis and HPLC
Clin. Chem., March 1, 1999; 45(3): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Dethy, M. A. Laute, N. Van Blercom, P. Damhaut, S. Goldman, and J. Hildebrand
Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients
Clin. Chem., May 1, 1997; 43(5): 740 - 744.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.